Rise in Cases of Sepsis and Antimicrobial Resistance (AMR) Along with the Focus on Preventative Care will Drive POCT Growth Throughout the Forecast Period
The rise in infectious diseases across Europe has led to a growing need for early detection and diagnosis of infectious diseases in the region. Point-of-care testing (POCT) is a vital part of the clinical diagnostics market and is rapidly evolving into the preferred testing mode as rapid infection diagnosis results in lower antibiotic intake, fewer lab tests for patients, and reduced treatment cost. This is cost-effective not just for patients but also for hospitals.
Obtaining the result pf a diagnostic test can take anything between a couple of hours to 3 days, depending on the disease. Rapid diagnosis is crucial for saving lives. New regulations, changing reimbursement laws, and technology advancements are all focusing on making tests accurate, operationally efficient, portable, and easy to use.
POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators and technology vendors. The stakeholders need to be abreast of the challenges posed by the industry as well as anticipate new avenues of growth to innovate new business models and capitalize on the transformation that the market is undergoing. It is pertinent to understand key convergences that drive infectious disease POCT sector growth and the technological building blocks that contribute to the future functionality of this market. This study will enable vendors in this space to look at future opportunities in infectious disease POCT industry from application area and technology points of view and also at organic and inorganic means to monetize these opportunities.
Research Scope
The research service provides an overview of the European infectious disease POCT market and provides a 5-year forecast from 2017 to 2022.
Geographic Scope: Western Europe (United Kingdom, Germany, France, Spain, Italy, Scandinavia (Denmark, Norway, Sweden, and Finland), and Benelux (Belgium, the Netherlands, and Luxembourg).
Research Highlights
The study highlights the key drivers and restraints in the market, the European regulatory landscape, current market dynamics, visioning scenarios, business model essentials, and key growth opportunities. The study includes the European market share along with the strategic imperatives for the infectious disease POCT market.
Key Issues Addressed
- What constitutes a complete infectious disease POCT vendor landscape?
- How is the competitive landscape been characterized? Which vendors are dominating the market?
- What are the growth opportunities in the infectious disease diagnostics space that can be leveraged by existing and future POCT participants?
- What are the key market trends in the infectious disease POCT market? How are product offerings in this market likely to emerge? How are transitions across the value chain solving the unmet needs from customers?
- What is the total market size and projected growth of POCT solutions for infectious diseases?
- How are current business models being replaced by innovative approaches to overcome existing challenges? What are the key market trends in the markets?
- What is the regulatory and reimbursement scenario for infectious disease POCT across Western Europe?
- Who are the game changing companies in this market segment?
- What are they key market opportunities that make this an attractive market with significant future revenue potential for companies?
